Details
Acronym: PHARMA-CAN
Reference: ProID2021010073
Partners: Instituto Tecnológico y de Energías Renovables (ITER) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC)
Duration: March 1, 2021 – April 4, 2023
Budget: 38.990,15€
Co-financing: ERDF / Government of the Canary Islands
Grant Program for the Implementation of R&D Projects by Research Organizations and Companies in the Priority Areas of the Smart Specialization Strategy of the Canary Islands (RIS-3). Co-financed by the Canary Islands ERDF 2014-2020 Operational Program.
Overview of the project
The overall objective of the PHARMA-CAN project is to contribute to the improvement of drug prescription by considering pharmacogenetic polymorphisms present in the Canarian population using whole exome sequencing. The aim is to reduce drug toxicity and adverse effects.
To achieve this, the variation in key genes and variants of interest from publicly available pharmacogenetic databases will be studied to determine the variation and frequency of existing variants in the study population. If necessary, the exome capture design will be modified to allow simultaneous study with genetic diagnosis.
PHARMA-CAN carries out its activities through a consortium formed by the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC) and ITER. On one hand, ITER is responsible for developing genomic protocols and deploying and maintaining all elements of the technological tool. On the other hand, FIISC contributes its knowledge in applying genomics in healthcare, conducts necessary analyses for comparisons, refines the proprietary database, and provides the clinical perspective of the project.
The results of this project will enable the automated extraction of pharmacogenetic variants of interest from exome sequencing data, contributing to the improvement of drug prescription. This will enhance the personalized medicine approach in the general population.
The PHARMA-CAN project will perform whole exome sequencing using next-generation DNA sequencing platforms and the supercomputing infrastructure available at ITER.
